Media
BIOPROCESS INTERNATIONAL: Subunit vaccines stimulate immune cells by delivering selected components of a pathogen of interest rather than the entire pathogen. Elicio Therapeutics is developing subunit vaccines that target a recipient’s lymph node to elicit a robust immune response.
BIOSPACE: Immuno-oncology has grown enormously in the last decade, and the COVID-19 pandemic has accelerated our knowledge of the immune system. Elicio Therapeutics published data on the preprint server, bioRxiv, describing preclinical research on its cancer vaccine that shows a lot of promise.
THE PHARMA LETTER: USA-based clinical-stage biotech Elicio Therapeutics has entered into a clinical supply agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors.
BIOSPACE: Building stronger companies requires the right leadership. This week, life sciences companies from across the globe pinpoint the Movers & Shakers who will best benefit their company.
BioRxIV, Drakes, et. al.
Presentation — Keystone Emerging Cellular Therapies Conference 2022, Dylan Drakes, PhD
Presentation — Vaccine Summit Boston 2022, Pete DeMuth, PhD
Presentation — STING & TLR — Targeting Therapies Summit 2022, Pete DeMuth, PhD
PHARMA’S ALMANAC: 2022 Milestones
PHARMA’S ALMANAC: Progress in Therapeutics